title: Therapeutic use of infliximab in sight threatening uveitis: retrospective analysis of efficacy, safety, and limiting factors.
authors.forename: B
authors.initials: B
authors.lastname: Bodaghi
authors.forename: E
authors.initials: E
authors.lastname: Bui Quoc
authors.forename: B
authors.initials: B
authors.lastname: Wechsler
authors.forename: T H C
authors.initials: TH
authors.lastname: Tran
authors.forename: N
authors.initials: N
authors.lastname: Cassoux
authors.forename: D
authors.initials: D
authors.lastname: Le Thi Huong
authors.forename: O
authors.initials: O
authors.lastname: Chosidow
authors.forename: S
authors.initials: S
authors.lastname: Herson
authors.forename: J-C
authors.initials: JC
authors.lastname: Piette
authors.forename: P
authors.initials: P
authors.lastname: LeHoang
mesh_terms: D000293:Adolescent; D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D000069285:Infliximab; D008297:Male; D009363:Neoplasm Proteins / Q000627:therapeutic use; D047889:Receptors, Tumor Necrosis Factor, Type II; D012189:Retrospective Studies; D016896:Treatment Outcome; D053319:Tumor Necrosis Factor Decoy Receptors; D014605:Uveitis / Q000188:drug therapy*
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D009363:Neoplasm Proteins; D047889:Receptors, Tumor Necrosis Factor, Type II; D053319:Tumor Necrosis Factor Decoy Receptors; D000069285:Infliximab